NDATOPICALSOLUTION
Approved
May 1980
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
2/8 — Basic
HIBISTAT (chlorhexidine gluconate) by Johnson & Johnson is clinical pharmacology periogard® (chlorhexidine gluconate oral rinse usp, 0. First approved in 1980.
Drug data last refreshed 19h ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
HIBISTAT is a topical chlorhexidine gluconate solution approved in 1980 that provides broad-spectrum antimicrobial activity against aerobic and anaerobic bacteria. It is indicated for surgical site infection and healthcare-associated infection prevention. The drug works through local antimicrobial action with ~30% oral cavity retention and minimal systemic absorption.
LOE Approaching
As a mature, off-patent product approaching loss of exclusivity, the HIBISTAT brand team is likely small and focused on retention and cost management rather than growth initiatives.
Mechanism of Action
CLINICAL PHARMACOLOGY PerioGard® (Chlorhexidine Gluconate Oral Rinse USP, 0.12%) provides antimicrobial activity during oral rinsing. The clinical significance of chlorhexidine gluconate oral rinse's antimicrobial activities is not clear. Microbiological sampling of plaque has shown a general…
Indications
Worked on HIBISTAT at Johnson & Johnson? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.